All In Biotech

NDA 219428 · Tonix

Tonmya

Cyclobenzaprine Hydrochloride · Sublingual

Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Aug 15, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

23 Phase 3, 6 recruiting

FAERS reports

8,698

4,949 serious, 715 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 14, 2026.

TONMYA ® is indicated for treatment of fibromyalgia in adults. TONMYA is indicated for the treatment of fibromyalgia in adults ( 1 ).

Mechanism: The mechanism of action of cyclobenzaprine for the treatment of fibromyalgia in adults is unknown. In in vitro pharmacology studies, cyclobenzaprine demonstrated functional antagonism of 5-HT 2A , α 1 -adrenergic, H 1 -histaminergic, and M 1 -muscarinic acetylcholine receptors. In addition, pharmacological studies in animals demonstrated a similarity between the effects of cyclobenzaprine and the structurally related TCAs, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TONMYA · CYCLOBENZAPRINE HYDROCHLORIDE 2.8MG · TABLET, SUBLINGUAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclobenzaprine" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain1,387
  • headache1,092
  • fatigue1,061
  • drug ineffective811
  • off label use771
  • nausea716
  • constipation711
  • back pain634
  • fall613
  • rheumatoid arthritis551
  • dyspnoea547
  • product dose omission issue519

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004119
2005123
2006110
200710
200824
200923
201069
2011103
201284
2013130
201497
2015137
2016192
2017206
2018295
2019321
2020480
2021620
2022917
2023942
20241,158
20251,245
20261,292

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 69 on PubMed

Sponsor: Tonix

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.